William Busse, MD James Wolfe, MD M William Storms, MD Sharon Srebro, MD Lisa Edwards, PhD Marty Johnson, MS Brian W. Bowers, PharmD Paula R. Rogenes, PhD Kathleen Rickard, MD Madison, Wisconsin; San Jose, California; Colorado Springs, Colorado; and Research Triangle Park, North Carolina Submitted, revised, March 23, 2001. This paper was presented, in part, at the annual meeting of the American College of Chest Physicians, Toronto, Ontario, November 8 - 12, 1998.From the University of Wisconsin Hospital and Clinics, Madison, Wisconsin (W.B.); the Allergy and Asthma Associates, Santa Clara Valley Research Center, San Jose, California (J.W.); Allergy and Asthma Associates, Colorado Springs, Colorado (W.S., S.S.); and Glaxo Wellcome Inc., Research Triangle Park, North Carolina (L.E., M.J., B.W.B., P.R.R, and K.R.) All requests for reprints should be addressed to William W. Busse, MD, University of Wisconsin Hospital and Clinics, H6/367 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792-2454. E-mail: wwb@medicine.wisc.edu.
References
Conclusions
Treatment with FP 88 mg twice daily was more effective than zafirlukast 20 mg twice daily or placebo in improving asthma control and patient-rated outcomes in patients with persistent asthma who were previously receiving short-acting b2-agonists alone.
Acknowledgments
We acknowledge the important contributions made by the clinical investigators in this study: Thomas Bell, MD, Missoula, MT; Robert Berkowitz, MD, Atlanta, GA; David Bernstein, MD, Cincinnati, OH; Paul Chervinsky, MD, North Dartmouth, MA; Jonathan Corren, MD, Los Angeles, CA; David Coutin, MD, Bend, OR; David Denmead, MD, Danville, CA; James Fish, MD, Philadelphia, PA; Charles Fogarty, MD, Spartanburg, SC; Pinkus Goldberg, MD, Indianapolis, IN; Marshall P. Grodofsky, MD, West Hartford, CT; Jay Grossman, MD, Tucson, AZ; Alan Heller, MD, San Jose, CA; Harold Kaiser, MD, Minneapolis, MN; Edward Kent, MD, South Burlington, VT; Kathy Lampl, MD, Rockville, MD; Allen Lieberman, MD, Austin, TX; Richard Lockey, MD, Tampa, FL; Stephen McGeady, MD, Philadelphia, PA; Jon Musmand, MD, Portland, ME; Anjuli Nayak, MD, Normal, IL; Gregory Neagos, MD, Ypsilanti, MI; John Oppenheimer, MD, Springfield, NJ; Frank Picone, MD, Tinton Falls, NJ; Jacob Pinnas, MD, Tucson, AZ; Gordon Raphael, MD, Bethesda, MD; Guy Settipane, MD, Providence, RI; William Sokol, MD, Newport Beach, CA; James Taylor, MD, Tacoma, WA; Robert Townley, MD, Omaha, NE. We also acknowledge the assistance of Cheryl Beale, MA, and Richard A. Rogers, MS, in the preparation and editing of this manuscript. This study was supported by a grant from GlaxoWellcome Inc., Research Triangle Park, North Carolina.
